Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 01 10 2018
accepted: 19 02 2019
entrez: 8 3 2019
pubmed: 8 3 2019
medline: 18 12 2019
Statut: epublish

Résumé

The aim of this study was to examine the natural history of brain involvement in adult-onset myotonic dystrophies type 1 and 2 (DM1, DM2). We conducted a longitudinal observational study to examine functional and structural cerebral changes in myotonic dystrophies. We enrolled 16 adult-onset DM1 patients, 16 DM2 patients, and 17 controls. At baseline and after 5.5 ± 0.4 years participants underwent neurological, neuropsychological, and 3T-brain MRI examinations using identical study protocols that included voxel-based morphometry and diffusion tensor imaging. Data were analyzed by (i) group comparisons between patients and controls at baseline and follow-up, and (ii) group comparisons using difference maps (baseline-follow-up in each participant) to focus on disease-related effects over time. We found minor neuropsychological deficits with mild progression in DM1 more than DM2. Daytime sleepiness was restricted to DM1, whereas fatigue was present in both disease entities and stable over time. Comparing results of cross-sectional neuroimaging analyses at baseline and follow-up revealed an unchanged pattern of pronounced white matter alterations in DM1. There was mild additional gray matter reduction in DM1 at follow-up. In DM2, white matter reduction was of lesser extent, but there were some additional alterations at follow-up. Gray matter seemed unaffected in DM2. Intriguingly, longitudinal analyses using difference maps and comparing them between patients and controls did not reveal any significant differences of cerebral changes over time between patients and controls. The lack of significant disease-related progression of gray and white matter involvement over a period of five years in our cohort of DM1 and DM2 patients suggests either a rather slowly progressive process or even a stable course of cerebral changes in middle-aged adult-onset patients. Being the first longitudinal neuroimaging trial in DM1 and DM2, this study provides useful additional information regarding the natural history of brain involvement.

Identifiants

pubmed: 30845252
doi: 10.1371/journal.pone.0213381
pii: PONE-D-18-28592
pmc: PMC6405094
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0213381

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Neural Plast. 2016;2016:2696085
pubmed: 27313901
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
JAMA Neurol. 2014 May;71(5):603-11
pubmed: 24664202
Neurol Sci. 2007 Mar;28(1):9-15
pubmed: 17385090
Neurology. 2001 Feb 13;56(3):336-40
pubmed: 11171898
Neuroimage. 2010 Jun;51(2):565-77
pubmed: 20178850
J Neurol Sci. 2014 Jun 15;341(1-2):73-8
pubmed: 24768314
PLoS One. 2016 Jun 03;11(6):e0156901
pubmed: 27258100
Neuromuscul Disord. 2014 May;24(5):445-52
pubmed: 24613228
PLoS One. 2014 Aug 12;9(8):e104697
pubmed: 25115999
J Neuromuscul Dis. 2018;5(4):523-537
pubmed: 30248061
Neurology. 2006 Jul 25;67(2):350-2
pubmed: 16864839
Eur J Neurol. 2016 Sep;23(9):1471-6
pubmed: 27323306
J Neuromuscul Dis. 2018;5(3):279-294
pubmed: 30040740
Schizophr Res. 2008 Jul;102(1-3):150-62
pubmed: 18439804
Fortschr Neurol Psychiatr. 2006 Nov;74(11):643-50
pubmed: 17103364
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
pubmed: 10860804
Brain. 2011 Dec;134(Pt 12):3530-46
pubmed: 22131273
Neurology. 2010 Apr 6;74(14):1108-17
pubmed: 20220122
J Neurol. 2010 Aug;257(8):1246-55
pubmed: 20221771
Neuroimage Clin. 2016 Jun 15;12:190-7
pubmed: 27437180
Stroke. 2001 Jun;32(6):1318-22
pubmed: 11387493
J Sleep Res. 1994 Mar;3(1):52-59
pubmed: 10607109
Neuroimage Clin. 2016 May 03;11:678-685
pubmed: 27330968
Neuromuscul Disord. 2017 Jan;27(1):61-72
pubmed: 27919548
PLoS One. 2015 Jun 26;10(6):e0130352
pubmed: 26114298
Med Image Anal. 2001 Jun;5(2):143-56
pubmed: 11516708
Neurology. 2017 Aug 29;89(9):960-969
pubmed: 28768849
Eur Neurol. 2015;73(3-4):247-56
pubmed: 25824277
Lancet Neurol. 2018 Aug;17(8):671-680
pubmed: 29934199
Neuroimage. 2006 Jul 15;31(4):1487-505
pubmed: 16624579
Funct Neurol. 2015 Jan-Mar;30(1):21-31
pubmed: 26214024
J Neurol. 2004 Jun;251(6):710-4
pubmed: 15311347
Arch Clin Neuropsychol. 2017 Jun 1;32(4):401-412
pubmed: 28164212
Neuromuscul Disord. 2003 Dec;13(10):813-21
pubmed: 14678804
J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):642-6
pubmed: 19211594
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Ann Neurol. 2008 Sep;64(3):255-65
pubmed: 18661561
Acta Myol. 2017 Mar;36(1):14-18
pubmed: 28690389
Biol Psychiatry. 1999 Mar 15;45(6):764-70
pubmed: 10188007
AJNR Am J Neuroradiol. 2009 Mar;30(3):539-43
pubmed: 19074546
Dev Psychol. 2004 Sep;40(5):813-22
pubmed: 15355168
Neuromuscul Disord. 2015 Jul;25(7):603-16
pubmed: 25802024
J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):963-7
pubmed: 20798200
J Neurol. 2008 Dec;255(12):1904-9
pubmed: 19224318
Neuromuscul Disord. 2015 Oct;25(10):813-23
pubmed: 26341263
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888

Auteurs

Carla Gliem (C)

Department of Neurology, University Hospital Bonn, Bonn, Germany.

Martina Minnerop (M)

Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany.
Center for Movement Disorders and Neuromodulation, Department of Neurology and Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

Sandra Roeske (S)

Department of Neurology, University Hospital Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Hanna Gärtner (H)

Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany.

Jan-Christoph Schoene-Bake (JC)

Life and Brain Center, Department of NeuroCognition-Imaging, Bonn, and Department of Epileptology, University Hospital Bonn, Bonn, Germany.
Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.

Sandra Adler (S)

Department of Neurology, University Hospital Bonn, Bonn, Germany.

Juri-Alexander Witt (JA)

Department of Epileptology, University Hospital Bonn, Bonn, Germany.

Felix Hoffstaedter (F)

Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany.
Institute of Clinical Neuroscience and Medical Psychology/ Institute of Systems Neuroscience, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

Christiane Schneider-Gold (C)

Department of Neurology, Ruhr-University Bochum, St. Josef Hospital, Bochum, Germany.

Regina C Betz (RC)

Institute of Human Genetics, University Bonn, Bonn, Germany.

Christoph Helmstaedter (C)

Department of Epileptology, University Hospital Bonn, Bonn, Germany.

Marc Tittgemeyer (M)

Max-Planck-Institute for Neurological Research, Cologne, Germany.

Katrin Amunts (K)

Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany.
C. and O. Vogt Institute for Brain Research, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Thomas Klockgether (T)

Department of Neurology, University Hospital Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Center for Rare Diseases Bonn (ZSEB), University Hospital Bonn, Bonn, Germany.

Bernd Weber (B)

Life and Brain Center, Department of NeuroCognition-Imaging, Bonn, and Department of Epileptology, University Hospital Bonn, Bonn, Germany.
Center for Economics and Neuroscience, University Bonn, Bonn, Germany.

Cornelia Kornblum (C)

Department of Neurology, University Hospital Bonn, Bonn, Germany.
Center for Rare Diseases Bonn (ZSEB), University Hospital Bonn, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH